How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

239 results for

Drug-induced Photosensitivity

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

83. Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management Full Text available with Trip Pro

antibodiesBleeding diathesisHypotensionAllergic reactionTransmission of blood-borne pathogens 1–7 Sessions/wk, 1–4 weekly cyclesExchange 1–2 times the blood volume with FFP or albumin as replacement 1–7 Sessions Variable $$$ Photopheresis Upregulation of costimulatory molecules, downregulation of T cells, immunoregulation via T-regulatory cells Vascular access complications, skin erythema, pruritus, nausea, rare drug-induced lupus or scleroderma-like syndrome Oral: 0.6 mg/kg (target level ≥50 ng/mL 2 h after

2015 American Heart Association

84. Salazopyrine (A07EC01 (intestinal anti-inflammatory agents)) - Ulcerative colitis, Crohn's disease in the colon, Rheumatoid arthritis

in the colon. Rheumatology: Rheumatoid arthritis". 1 Akobeng et al. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s Disease, the Cochrane library 2005, Issue 2. 2 Travis et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: current management, Gut 2006; 55; 16-35 HAS - Medical, Economic and Public Health Assessment Division 3/15 03.2 Dosage "For oral use. The tablets must be swallowed with water, preferably after meals and must (...) ), pancreatitis. Skin and subcutaneous tissue disorders Exanthema, urticaria, skin colouration and more rarely: cyanosis, epidermal necrolysis (Lyell's syndrome), Stevens-Johnson syndrome, exfoliative dermatitis, photosensitivity, alopecia, lichen planus. Musculoskeletal and connective tissue disorders Rare: systemic lupus erythematosus, arthralgia, myalgia. Systemic Symptoms (DRESS) syndrome. This syndrome includes a severe skin rash, fever, eosinophilia above 1500/mm3 and/or atypical lymphocytosis

2015 Haute Autorite de sante

85. Xalkori (crizotinib)

cancer has been demonstrated and its safety is acceptable in view of its observed benefits. The occurrence of pneumonitis, interstitial lung disease, QT prolonged, bradycardia, hepatotoxicity, visual disturbance, neutropenia/leukopenia, neuropathy, renal cyst, and photosensitivity, as well as the safety of the product in patients with hepatic impairment or severe renal impairment need to be further investigated via post-marketing surveillance. As a result of its regulatory review, the Pharmaceuticals

2012 Pharmaceuticals and Medical Devices Agency, Japan

87. Tasimelteon (Hetlioz)

period ( t) that governs circadian rhythms is typically a little over 24 hours and ranges between 23.5 and 24.7 hours in healthy sighted individuals. These rhythms are synchronized (entrained) to the 24-hour day by exposure to environmental time cues, the strongest of which is the daily light-dark cycle, detected primarily by the photosensitive ganglion cells of the retina. In the absence of light input, synchronization with the 24-hour day is lost; consequently the circadian rhythms follow

2013 FDA - Drug Approval Package

89. Seebri Breezhaler - glycopyrronium bromide

, alkaline and neutral conditions) and hygroscopicity (58% RH and 75% RH 1 week/80% RH and 93% RH 1 day). Seebri Breezhaler CHMP assessment report EMA/CHMP/508029/2012 Page 9/84 Results obtained from the submitted stability program indicate very good stability of glycopyrronium bromide in the solid state. No evidence of instability was observed under long term or accelerated conditions when samples were stored in the proposed container closure system. Glycopyrronium bromide was not photosensitive

2012 European Medicines Agency - EPARs

90. Inlyta - axitinib

Contrast Enhanced Magnetic Resonance Imaging DDPS Detailed description of the pharmacovigilance system DILI Drug-induced liver injury DLT Dose Limiting Toxicity DMC Data Monitoring Committee DR Duration of response EC50 half maximal effective concentration ECG Electrocardiogram ECOG Eastern Cooperative Oncology Group ECOGPS ECOG performance status EGFR Epidermal growth factor receptor EORTC Eastern Cooperative Oncology Group EuroQoL European Quality of Life EQ-5D EuroQol EQ-5D self-report questionnaire

2012 European Medicines Agency - EPARs

91. Enurev Breezhaler - glycopyrronium bromide

, alkaline and neutral conditions) and hygroscopicity (58% RH and 75% RH 1 week/80% RH and 93% RH 1 day). Enurev Breezhaler CHMP assessment report EMA/CHMP/508338/2012 Page 9/84 Results obtained from the submitted stability program indicate very good stability of glycopyrronium bromide in the solid state. No evidence of instability was observed under long term or accelerated conditions when samples were stored in the proposed container closure system. Glycopyrronium bromide was not photosensitive

2012 European Medicines Agency - EPARs

92. Tovanor Breezhaler - glycopyrronium bromide

CHMP assessment report EMA/CHMP/508244/2012 Page 9/84 exposed to acid, alkaline and neutral conditions) and hygroscopicity (58% RH and 75% RH 1 week/80% RH and 93% RH 1 day). Results obtained from the submitted stability program indicate very good stability of glycopyrronium bromide in the solid state. No evidence of instability was observed under long term or accelerated conditions when samples were stored in the proposed container closure system. Glycopyrronium bromide was not photosensitive

2012 European Medicines Agency - EPARs

95. KHA-CARI adaptation of the KDIGO Guideline for the Care of Kidney Transplant Recipients

captures drug dosages, though not concentrations, which serve as a surrogate marker for impact of TDM only. Audit of use of therapeutic drug monitoring and its consequences for patient and graft outcomes could be undertaken at individual sites. BACKGROUND In almost all cases, immunosuppression for the prevention of allograft rejection is a pre-requisite for successful transplantation. However, acute and chronic immunosuppressant drug-induced toxicities are common, as is evidence of acute and chronic

2012 KHA-CARI Guidelines

96. Study to Evaluate Efficacy and Safety of MP1032 in Patients With Chronic Plaque Psoriasis

malignancy or history of malignancy, except for basal cell and actinic keratosis. Basal cell carcinoma of the skin or in situ cervical carcinoma that have been fully treated and show no evidence of recurrence are allowed. Positive HIV-Antibody, HBs-Antigen or HCV-Antibody-Test at screening. Previous strong sun exposure (e.g. sea holiday) within 28 days or UV treatment within 24 weeks before IMP initiation. Known photo allergy and / or experienced drug-induced photo toxicity. Elective (planned (...) ) hospitalization or medical intervention preventing patient from following the protocol requirements. Prior treatment not adhering to defined drug classes and related washout periods (Protocol table 2.) Planned use of any ultraviolet (UV) phototherapy or photochemotherapy / photosensitizing drugs during the course of the trial and within 28 days/24 weeks following the last dose of the IMP. Patients with a history of chronic alcohol or drug abuse within 6 months of IMP initiation. Patients with a blood pressure

2018 Clinical Trials

97. Photodynamic Therapy Mediated by Aloe-Emodin Inhibited Angiogenesis and Cell Metastasis Through Activating MAPK Signaling Pathway on HUVECs Full Text available with Trip Pro

cells. In the present study, we investigated the mechanisms of photocytotoxicity induced by aloe-emodin in human umbilical vein endothelial cells. Analysis of cell proliferation results noted a significant decrease in cultured cells which received various concentrations of aloe-emodin and photodynamic therapy-induced light doses. Additionally, mitochondrial mechanisms of apoptotic cell death were observed in aloe-emodin photodynamic therapy-treated cells, as tube formation assays noted angiogenesis (...) Photodynamic Therapy Mediated by Aloe-Emodin Inhibited Angiogenesis and Cell Metastasis Through Activating MAPK Signaling Pathway on HUVECs Photodynamic therapy is a clinically used, minimally invasive therapeutic procedure that involves the application of photosensitizers which can locate in target cells and so be irradiated at a corresponding wavelength. Laser light irradiation activation of photosensitizers generates free reactive oxygen species, which induces selective cytotoxic activity

2018 Technology in cancer research & treatment

98. Photodermatoses in skin of color. (Abstract)

Photodermatoses in skin of color. Photodermatoses represent a heterogeneous collection of disorders unified by the characteristic of being provoked through exposure to ultraviolet radiation. Generally, these conditions are classified into the following categories: immunologically mediated photodermatoses, chemical- and drug-induced photosensitivity, photoaggravated dermatoses and photosensitivity associated with defective DNA repair mechanisms or chromosomal instabilities. The list (...) of photodermatoses is extensive, and each individual photodermatosis is understood to a different extent. Regardless, there exists a paucity of information with regards to the clinical presentation among those with skin of colour. With ever-changing global demographics, recognition of photosensitive disorders in a diverse population is essential for accurate diagnoses and therapeutic guidance. The scope of this article seeks to review the epidemiology and clinical variability in presentation

2018 Journal of the European Academy of Dermatology and Venereology

100. Lipanthyl (fenofibrate) - hypertriglyceridaemia or hyperlipidaemia

the ACCORD study in women treated by lipid-lowering combinations. As HAS - Medical, Economic and Public Health Assessment Division 9/11 regards the Abbot products, the analysis was extended to include other risks (hypercholesterolaemia, cholelithiasis, pancreatitis, myopathy/rhabdomyolysis, drug-induced hepatitis, increase in CPK, photosensitivity, venous thromboembolic disease, risk of developing diabetes and hyperglycaemia with statins in addition to the potential risk of major cardiovascular events

2014 Haute Autorite de sante

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>